DetailsCategory: AntibodiesPublished on Friday, 24 July 2020 14:39Hits: 200 STOCKHOLM, Sweden I July 24, 2020 I Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced that the Committee for Medicinal Products for Human use (CHMP) has adopted a negative opinion recommending a refusal of the marketing authorisation for emapalumab for the treatment of primary haemophagocytic lymphohistiocytosis (HLH) in children under 18 years of age in Europe.
Recent Comments